141:
UNIT OF ALLERGY IN AN ONCOLOGY INSTITUTE. FIRST NATIONALE EXPERIENCE in SPAIN . ABOUT THE FIRST 800 DESENSITIZATIONS TO CHEMOTHERAPEUTICS AND MONOCLONAL ANTIBODIES
Saturday, March 3, 2018
South Hall A2 (Convention Center)
Enrique A Martí-Guadano, PhD
UNIT OF ALLERGY IN AN ONCOLOGY INSTITUTE. FIRST NATIONALE EXPERIENCE in SPAIN. ABOUT THE FIRST 800 DESENSITIZATIONS TO CHEMOTHERAPEUTICS AND MONOCLONAL ANTIBODIES

Enrique Martí-Guadano (1)Carolina Escobar (1) Natalia Marti (1) Leopoldo Pau (2) Silvia Corrales (2) Mariana Castells (3)
(1) Institut Català Oncològic (2) Unitat Diagnòstic Al.lèrgia Medicamentosa. UDAM. Barcelona . Spain (3) Brigham and Women’s Hospital. Boston. USA

RATIONALE: The Institut Català d'Oncologia, (ICO), publishes 4 per thousand of adverse reactions to chemotherapy, mediated or not by allergic mechanisms, and, in most cases, leaving the first therapeutic lines, for second one, safer, but less effective and undoubtedly higher direct costs.
Our aim, to reverse that process, to get the opportunity to keep those patients with the best of possible medications.

METHODS:
2 Part-time allergists, 1 nurse specialized in drug allergy, 1 Pharmaceutical, under the coordination of 1 Head of Unit
First visit, skin tests, risk stratification and desensitization decision, place and number of steps
The desensitization protocols used are from Brigham and Women's Hospital of Boston

RESULTS: 285 patients, with different types and stages of cancer; 801 cycles of desensitization, mainly to Platins and taxanes; 98% of successes (reaching final dose prescribed by oncologist) 70% were 12-step cycles and 25% of 16; All in Day Hospital

CONCLUSIONS: A Chemotherapy Drug Desensitization Unit, managed by allergists, increases the population's survival expectations with cancer, being able to maintain the first therapeutic line, recommended by the international guidelines, and that of another Form, they are confronted with second choices, safer perhaps, but clearly less effective